 0 Table of Contents |
  1 Home |
  2 Examples |
  3 Artifacts Summary |
   3.1 EMA Write API ActivityDefinition |
   3.2 EMA Write API ActivityDefinition Restrictions |
   3.3 EMA Write API Marketing Regulated Authorization |
   3.4 EMA Write API MedicinalProductDefinition |
   3.5 EMA Write API MedicinalProductDefinition Restrictions |
   3.6 EMA Write API PackagedProductDefinition |
   3.7 EMA Write API PackagedProductDefinition |
   3.8 EMA Write API Regulated Authorization |
   3.9 EMA Write PMS API Bundle |
   3.10 EMA Write PMS API Bundle Restrictions |
   3.11 EMA AdditionalMonitoringIndicator boolean CodeableConcept |
   3.12 EMA API V2 Identifier |
   3.13 EMA Application Identifier Number |
   3.14 EMA ATC Coding |
   3.15 EMA Coding |
   3.16 EMA Coding Restrictions |
   3.17 EMA Duration |
   3.18 EMA Eudra GMP Number Identifier |
   3.19 EMA EURD Identifier |
   3.20 EMA Generic ReferentialTerm CodeableConcept |
   3.21 EMA Generic ReferentialTerm CodeableConcept restrictions |
   3.22 EMA Genetically Modified Organisms CodeableConcept |
   3.23 EMA Identifier Restrictions |
   3.24 EMA Legal Basis CodeableConcept |
   3.25 EMA Light ATC CodeableConcept |
   3.26 EMA Manufacturing Authorization Number Identifier |
   3.27 EMA Marketing Authorization Identifier |
   3.28 EMA Master File Identifier |
   3.29 EMA Master File Identifier Restrictions |
   3.30 EMA Master Identifier |
   3.31 EMA MP Identifier |
   3.32 EMA PC Identifier |
   3.33 EMA Period |
   3.34 EMA Period restrictions |
   3.35 EMA Pharmacovigilance Qualified Person Type CodeableConcept |
   3.36 EMA Pharmacovigilance Qualified Person Type CodeableConcept |
   3.37 EMA Product Category CodeableConcept |
   3.38 EMA Quantity |
   3.39 EMA Ratio |
   3.40 EMA Reference Restrictions |
   3.41 EMA XEVMPD Product CodeableConcept |
   3.42 The MPD Name Part Type Coding |
   3.43 Authorised Dose Form |
   3.44 Code System Name |
   3.45 Date of Update extension |
   3.46 Language |
   3.47 Marketing Status Reason |
   3.48 MedicinalProductDefiniton - MasterFile |
   3.49 Regulated Authorization - Date of First Authorisation |
   3.50 Regulated Authorization - International Birth Date |
   3.51 Regulated Authorization - Paediatric - Reference Country |
   3.52 Risk of Supply Shortage |
   3.53 Risk of Supply Shortage Comment |
   3.54 Submission Date extension |
   3.55 Term Version |
   3.56 The ATC Pending Extension |
   3.57 The Comparator Extension |
   3.58 The Complies with directive Extension |
   3.59 The Ingredient Annex 5.10 Extension |
   3.60 The Ingredient Annex 5.11 Extension |
   3.61 The Ingredient Annex 5.20 Extension |
   3.62 The Ingredient Annex 5.23 Extension |
   3.63 The Ingredient Documentation Extension |
   3.64 The Ingredient's Origin of Substance Extension |
   3.65 The Operation Extension |
   3.66 The Package Shelf Life Duration Extension |
   3.67 Additional Monitoring Indicator |
   3.68 Application Submission Type |
   3.69 Authorised Dose Form |
   3.70 Combined Pharmaceutical Dose Form |
   3.71 Country |
   3.72 Data Classification |
   3.73 Documentation |
   3.74 Domain |
   3.75 Genetically Modified Organism |
   3.76 Ingredient Role |
   3.77 Language |
   3.78 Legal Status of Supply |
   3.79 Manufacturing Activity |
   3.80 Marketing and Manufacturing types |
   3.81 Marketing Status |
   3.82 Marketing Status Reason |
   3.83 Master File Identifier Type |
   3.84 Master File Type |
   3.85 Master File Type + DocumentType |
   3.86 Material |
   3.87 Medicinal Product Name Part Type |
   3.88 Medicinal Product Type |
   3.89 Packaging |
   3.90 Paediatric Use Indicator |
   3.91 Pharmaceutical Dose Form |
   3.92 Product Category |
   3.93 Product Cross Reference Type |
   3.94 Promotion |
   3.95 Quantity Operator |
   3.96 Record Status |
   3.97 Regulatory Authorization Registration Procedure |
   3.98 Regulatory Entitlement Status |
   3.99 Regulatory Entitlement Type |
   3.100 Shelf Life Type |
   3.101 Special Precautions For Storage |
   3.102 Substance Origin |
   3.103 Supply |
   3.104 Unit of Measurement |
   3.105 Units of Presentation |
   3.106 XEVMPD medicinal product type |
   3.107 XEVMPD medicinal product type |
   3.108 Additional Monitoring Indicator |
   3.109 Application Submission Type |
   3.110 Combination Package |
   3.111 Combined Pharmaceutical Dose Form |
   3.112 Combined Term |
   3.113 Contact Type |
   3.114 Country |
   3.115 Data Classification |
   3.116 Document Type |
   3.117 Documentation |
   3.118 Domain |
   3.119 Genetically Modified Organism |
   3.120 Ingredient Role |
   3.121 Language |
   3.122 Legal Status From the Supply |
   3.123 Manufacturing Activity Value Set |
   3.124 Marketing Authorisation Application Legal Basis |
   3.125 Marketing Status |
   3.126 Master File Identifier Type |
   3.127 Master File Type |
   3.128 Material |
   3.129 Medicinal Product Name Part Type |
   3.130 Medicinal Product Type |
   3.131 Packaging |
   3.132 Paediatric Use Indicator |
   3.133 Pharmaceutical Dose Form |
   3.134 Product Category |
   3.135 Product Cross Reference Type |
   3.136 Promotion |
   3.137 Quantity Operator |
   3.138 Reason for Marketing Unavailability |
   3.139 Record Status |
   3.140 Regulatory Authorization Registration Procedure |
   3.141 Regulatory Entitlement |
   3.142 Regulatory Entitlement Status |
   3.143 Shelf Life Type |
   3.144 Special Precautions for Storage |
   3.145 Substance Origin |
   3.146 Supply |
   3.147 Unit Of Measurement Value Set |
   3.148 Units Of Presentation |
   3.149 XEVMPD Medicinal Product Type |
   3.150 1. Get Product Bundle |
   3.151 2. Change pack size |
   3.152 3. Change pack size (response) |
   3.153 4. Add manufacturing operation |
   3.154 5. Add manufacturing operation (response) |
   3.155 ActivityDefinition |
   3.156 DocumentReference |
   3.157 DocumentReference |
   3.158 Organization |
   3.159 PractitionerRole |